The agency approved Abbott’s Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices. The devices can help cut the risk of abnormal heart rhythms and restore the natural patterns of heart rhythms.
The devices also pair with Abbott’s myMerlinPulse application, which allows physicians to continuously monitor their patients remotely and provides access to data. The smartphone app is compatible with both Apple and Android phones.
More articles on cardiology:
5 best children’s hospitals for cardiology and heart surgery, ranked by US News
FDA clears Apple Watch ECG for remote patient visits during pandemic: 6 things to know
Cincinnati Children’s to develop mobile rheumatic heart disease tech
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.